Ozempic, GLP-1 Drugs & the Holistic Alternative

The Body’s Natural GLP-1 System

GLP-1 is naturally secreted after eating. A healthy gut, balanced microbiome, and whole-food diet enhance this process, while inflammation, obesity, and stress weaken it.

Factors That Reduce GLP-1 Secretion^28-30

• High sugar and fatty acid levels (glucolipotoxicity)
• Gut microbiome imbalances from processed foods or toxins
• Chronic inflammation and obesity
• Type 2 diabetes, insulin resistance, and metabolic stress
• Poor sleep, chronic stress, and sedentarism
• Highly processed foods and environmental toxins

How to Naturally Stimulate GLP-1 Release

Macronutrients and Meal Composition

• Proteins and Amino Acids:Foods rich in glutamine, phenylalanine, tryptophan, and L-valine can stimulate GLP-1^31-35.
• Healthy Fats:Monounsaturated and polyunsaturated fatty acids, as well as long-chain fatty acids^1,35.
• Dietary Fiber and Slow-Digesting Foods:High-fiber foods (whole grains, nuts, avocados) and foods that slow digestion (viscous fibers, encapsulated nutrients)^35,36.
  
  

Bioactive Compounds and Phytochemicals

• Polyphenols and Flavonoids:Compounds like quercetin, curcumin, anthocyanins, rutin, and (-)-epicatechin enhance GLP-1 secretion^37-42.
• Other Plant Compounds:Capsaicin (from chili peppers), ginsenosides (from ginseng), and certain herbal extracts also promote GLP-1 secretion³⁷.
  
  

Gut Microbiota and Metabolites

• Short-Chain Fatty Acids (SCFAs):produced by fiber fermentation directly signal L-cells to release GLP-1³⁵.
• Specific Bacterial Proteins: Akkermansia muciniphila and other beneficial bacteria further support gut-hormone signaling⁴³.
  
  

A diet rich in protein, specific amino acids, healthy fats, fiber, and plant polyphenols can naturally enhance GLP-1 secretion, supporting metabolic health and glucose control. This means that instead of outsourcing GLP-1 to drugs, we can teach the body to regulate satiety and metabolism effectively – using food and lifestyle as medicine.

Oasis Holistic Alternatives to Support Blood Sugar & Metabolism

Plant-Based, Whole Living Foods

At An Oasis of Healing, we emphasize a whole, living plant foods – sprouts, microgreens, vegetables, fruits, nuts, and seeds – rich in:

• Fiber – slows digestion, enhances GLP-1 release, and stabilizes blood sugar^35,36.
• Phytonutrients – promote GLP-1 secretion, reduce inflammation and improve insulin sensitivity^37-42.
• Enzymes and antioxidants: Certain dietary antioxidants – such as (-)-epicatechin and anthocyanins – stimulate GLP-1 secretion by activating intestinal signaling pathways, while GLP-1 itself enhances the body’s antioxidant defenses^39,44.
  
  

Research supports that diets high in fiber, healthy fats, and polyphenols naturally enhance GLP-1 and glucose regulation^1,31-43.

Fasting & Meal Timing

Intermittent fasting and time-restricted eating can reset metabolism and improve hormone balance. Studies show fasting:^45-47:

• Enhances GLP-1 release
• Improves insulin sensitivity
• Reduces inflammation
  
  

At An Oasis of Healing, fasting and green juice feasting are integral to Dr. Thomas Lodi’s programs, helping detoxify the body and reset hunger and satiety pathways

Movement, Sleep, and Stress

Movement

Regular exercise and habitual physical activity enhance GLP-1 secretion. Both acute and chronic exercise increase postprandial (after eating) GLP-1 responses, improve glucose regulation, and may help restore healthy GLP-1 rhythms, especially in those with obesity or metabolic risk. Mechanistically, exercise can influence circadian genes and metabolic pathways that support GLP-1 release^48-50.

Unlike pharmaceutical GLP-1 agonists, exercise offers comprehensive benefits—improving insulin sensitivity, cardiovascular function, mood, and especially muscle preservation. One concern with GLP-1 drugs such as semaglutide is the loss of lean muscle mass during weight reduction. In contrast, regular resistance and aerobic exercise, combined with adequate protein intake, supports muscle maintenance and metabolic health, helping to counteract this effect^51-53.

Sleep and Circadian Disruption^48,54

Poor sleep, sleep deprivation, and circadian rhythm disruption negatively affect GLP-1 secretion. Short sleep duration, irregular sleep-wake cycles, and exposure to artificial light at night can blunt or dysregulate GLP-1’s normal daily rhythm, leading to impaired glucose regulation and increased metabolic risk. Poor sleep also decreases leptin (satiety hormones) while increasing ghrelin (hunger hormone). Adequate, regular sleep supports optimal GLP-1 secretion.

Chronic Stress^1-55

Chronic stress can alter GLP-1 signaling, particularly in the brain, and may amplify stress-related metabolic disturbances. Central GLP-1 pathways are involved in the body’s response to both acute and chronic stress, influencing appetite, glucose homeostasis, and the hypothalamic-pituitary-adrenal (HPA) axis. Chronic stress may dysregulate these pathways, potentially leading to abnormal GLP-1 responses and subsequent metabolic consequences.

Chronic stress raises cortisol, which increases cravings for sugar and disrupts blood sugar control. Mind-body practices – meditation, breathwork, and yoga – used at An Oasis of Healing help restore hormonal balance and calm the HPA axis.

The Role of the Gut Microbiome

The gut microbiome plays a central role in GLP-1 secretion, through^56-58:

• Fiber fermentation: Beneficial gut bacteria break down dietary fiber into short-chain fatty acids (SCFAs) like butyrate and propionate, which signal intestinal L-cells to release GLP-1.
• Bile acid signaling: Microbes modify bile acids that activate receptors (such as TGR5), further enhancing GLP-1 secretion.
• Dysbiosis: Imbalances in gut bacteria—common in obesity and diabetes—can reduce GLP-1 release and sensitivity, impairing metabolic health.
  
  

Ways to support microbiome health:

• Eat fiber-rich foods (sprouted beans and whole grains, leafy greens, root vegetables, chia and flax seeds).
• Include fermented foods (tempeh, miso, sauerkraut, kimchi).
• Eat prebiotic foods (onions, garlic, leeks, asparagus).
  
  

Risks of Over-Reliance on Pharmaceuticals

While GLP-1 drugs offer short-term results, they come with certain risks:

• Nutrient deficiencies from impaired digestion and reduced food intake.
• Dependency, as weight often returns after discontinuation. Do you want to take this medication for the rest of your life?
• Ignoring root causes, such as poor diet, stress, insufficient sleep, and microbiome imbalance.
• Short and long-term side effects may be even more detrimental to health.
  
  

This pharmaceutical-centered model focuses on managing symptoms, whereas holistic care seeks to restore natural balance.

The Holistic Approach at An Oasis of Healing

Our philosophy is simple: stop creating the conditions for illness, and the body will naturally heal. Under the guidance of Dr. Thomas Lodi, our approach combines:

• Whole, living foods nutrition provides natural GLP-1 stimulation and deep nourishment.
• Fasting protocols and green juice cleanses reset metabolism and satiety/ hunger regulation, and promote cellular repair.
• Enhancement therapies, such as colonics and lymphatics, reduce the toxic load that drives metabolic dysfunction.
• Mind-body therapies reduce stress and restore hormonal balance.
  
  

This integrative method supports weight balance, blood sugar regulation, and cellular healing—key for cancer recovery and lifelong wellness.

Conclusion

GLP-1 drugs like Ozempic® reveal the power of the body’s natural satiety systems – but they are not the only path. Through whole foods, fasting, microbiome health, movement, stress reduction, and sleep, we can activate GLP-1 naturally and sustainably.

At An Oasis of Healing, we believe true healing happens by working with the body, not overriding it with pharmaceuticals. By returning to nature’s design – nourishing food, balanced living, and mind-body harmony – we can achieve what no drug can: lasting vitality and metabolic balance.

References

1. Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al.
   Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019; 30: 72–130. https://doi.org/10.1016/j.molmet.2019.09.010.
2. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 Apr 3;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001. PMID: 29617641.
3. Jean-Philippe Krieger et al. “Glucagon-Like Peptide-1 Links Ingestion, Homeostasis, and the Heart..” Comprehensive Physiology, 15 1 (2024): e7. https://doi.org/10.1002/cph4.7.
4. J. Holst et al. “The physiology of glucagon-like peptide 1.” Physiological reviews, 87 4 (2007): 1409-39 . https://doi.org/10.1152/PHYSREV.00034.2006.
5. Catanese L. Harvard Health Publishing. GLP-1 diabetes and weight-loss drug side effects: “Ozempic face” and more. Feb 05, 2024. [Internet]. [cited 2025 Oct 06]. Available from: https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more.
6. J. Ussher et al. “Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.” Nature Reviews Cardiology, 20 (2023): 463 – 474. https://doi.org/10.1038/s41569-023-00849-3.
7. Sattar, N., Lee, M., Kristensen, S., Branch, K., Del Prato, S., Khurmi, N., Lam, C., Lopes, R., McMurray, J., Pratley, R., Rosenstock, J., & Gerstein, H. (2021). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/S2213-8587(21)00203-5.
8. M. Nauck et al. “GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art.” Molecular Metabolism, 46 (2020). https://doi.org/10.1016/j.molmet.2020.101102.
9. Jennifer M. Trujillo et al. “GLP-1 receptor agonists: an updated review of head-to-head clinical studies.” Therapeutic Advances in Endocrinology and Metabolism, 12 (2021). https://doi.org/10.1177/2042018821997320.
10. Richard Le et al. “Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.” Journal of Clinical Medicine, 13 (2024). https://doi.org/10.3390/jcm13164674.
11. Johanna Helmstädter et al. “Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor.” British Journal of Pharmacology, 179 (2021): 659 – 676. https://doi.org/10.1111/bph.15462.
12. Xin Zhao et al. “GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.” Frontiers in Endocrinology, 12 (2021). https://doi.org/10.3389/fendo.2021.721135.
13. S. Madsbad et al. “The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.” Expert Opinion on Investigational Drugs, 34 (2025): 197 – 215. https://doi.org/10.1080/13543784.2025.2472408.
14. G. Bendotti et al. “The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists..” Pharmacological research (2022):106320. https://doi.org/10.1016/j.phrs.2022.106320.
15. Khalid M Hamed et al. “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.” Cureus, 16 (2024). https://doi.org/10.7759/cureus.68390
16. Louise Buonalumi Tacito Yugar et al. “The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis.” Diabetology & Metabolic Syndrome, 16 (2024). https://doi.org/10.1186/s13098-024-01337-5
17. S. Wharton et al. “Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.” Postgraduate Medicine, 134 (2021): 14 – 19. https://doi.org/10.1080/00325481.2021.2002616